BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12420208)

  • 1. Generation of alloreactive anti-leukemic cytotoxic T lymphocytes with attenuated GVHD properties from haploidentical parents in childhood acute lymphoblastic leukemia.
    Jurickova I; Waller EK; Yeager AM; Boyer MW
    Bone Marrow Transplant; 2002 Nov; 30(10):687-97. PubMed ID: 12420208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune response of post-transplant peripheral lymphocytes against the patient pre-B cell line, NAGL-1.
    Kasai M; Akatsuka Y; Emi N; Taji H; Kohno A; Abe A; Tanimoto M; Kodera Y; Saito H
    Int J Hematol; 1999 Feb; 69(2):112-8. PubMed ID: 10071461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-15 favors the expansion of central memory CD8+ T cells in ex vivo generated, antileukemia human cytotoxic T lymphocyte lines.
    Daudt L; Maccario R; Locatelli F; Turin I; Silla L; Montini E; Percivalle E; Giugliani R; Avanzini MA; Moretta A; Montagna D
    J Immunother; 2008 May; 31(4):385-93. PubMed ID: 18391757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.
    Barbui AM; Borleri G; Conti E; Ciocca A; Salvi A; Micò C; Introna M; Rambaldi A
    Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-cell cloning of human, donor-derived antileukemia T-cell lines for in vitro separation of graft-versus-leukemia effect from graft-versus-host reaction.
    Montagna D; Daudt L; Locatelli F; Montini E; Turin I; Lisini D; Giorgiani G; Bernardo ME; Maccario R
    Cancer Res; 2006 Jul; 66(14):7310-6. PubMed ID: 16849581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation.
    Blair A; Goulden NJ; Libri NA; Oakhill A; Pamphilon DH
    Blood Rev; 2005 Nov; 19(6):289-300. PubMed ID: 16275419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the emergence and persistence of donor-derived leukaemia-reactive cytotoxic T lymphocytes protect patients given an allogeneic BMT from recurrence? Results of a preliminary study.
    Montagna D; Locatelli F; Calcaterra V; Comoli P; Moretta A; Giorgiani G; Zecca M; Bonetti F; Giraldi E; Rondini G; Maccario R
    Bone Marrow Transplant; 1998 Oct; 22(8):743-50. PubMed ID: 9827970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Graft-versus-leukemia effect by lymphocytes from the first donor after second cord blood transplantation in a patient with T-lymphoblastic lymphoma].
    Nagai K; Hashimoto H; Itoh K; Matsushita A; Shimoji S; Kimura T; Inoue D; Mori M; Nagai Y; Tabata S; Yanagida M; Takahashi T
    Rinsho Ketsueki; 2010 Jun; 51(6):413-21. PubMed ID: 20622488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue-restricted T cell alloresponses across HLA barriers: selection and identification of leukemia-restricted CTL in HLA-mismatched stimulator-responder pairs.
    Fujiwara H; Sconocchia G; Melenhorst J; Eniafe R; Nakamura R; Hensel N; Barrett AJ
    Bone Marrow Transplant; 2003 Aug; 32(4):371-8. PubMed ID: 12900773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human gammadelta(+) T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response.
    Lamb LS; Musk P; Ye Z; van Rhee F; Geier SS; Tong JJ; King KM; Henslee-Downey PJ
    Bone Marrow Transplant; 2001 Mar; 27(6):601-6. PubMed ID: 11319589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD.
    Bishara A; De Santis D; Witt CC; Brautbar C; Christiansen FT; Or R; Nagler A; Slavin S
    Tissue Antigens; 2004 Mar; 63(3):204-11. PubMed ID: 14989709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
    Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation.
    Koehl U; Sörensen J; Esser R; Zimmermann S; Grüttner HP; Tonn T; Seidl C; Seifried E; Klingebiel T; Schwabe D
    Blood Cells Mol Dis; 2004; 33(3):261-6. PubMed ID: 15528141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haploidentical transplantation for acute lymphoblastic leukemia in childhood.
    Klingebiel T; Handgretinger R; Lang P; Bader P; Niethammer D
    Blood Rev; 2004 Sep; 18(3):181-92. PubMed ID: 15183902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Presence of low dose of fludarabine in cultures blocks regulatory T cell expansion and maintains tumor-specific cytotoxic T lymphocyte activity generated with peripheral blood lymphocytes.
    Hegde U; Chhabra A; Chattopadhyay S; Das R; Ray S; Chakraborty NG
    Pathobiology; 2008; 75(3):200-8. PubMed ID: 18550918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of HLA-A2 subtype specific cytotoxic T lymphocytes from cord blood used for cord blood stem cell transplantation.
    Yazaki M; Takahashi T; Ito Y; Ito T; Mori C; Wada Y
    Bone Marrow Transplant; 2000 Aug; 26(4):451-3. PubMed ID: 10982294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA-mismatched cord blood transplantation: immunological studies.
    Vilmer E; Quelvennec E; Plouvier E; Denamur E; Rohrlich P; Elion J; Sterkers G
    Blood Cells; 1994; 20(2-3):235-41. PubMed ID: 7538336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody.
    Csóka M; Strauss G; Debatin KM; Moldenhauer G
    Leukemia; 1996 Nov; 10(11):1765-72. PubMed ID: 8892680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.